Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 6/20 | 0.53 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517525 | 0.95 | MCL1 (0.51) | MCL1DPP4CCNA2CDK2CCNA1 | |
| SCHEMBL17102972 | 0.93 | MCL1 (0.50) | MCL1MAOAMAOB | |
| SCHEMBL17102962 | 0.93 | MCL1 (0.50) | MCL1MAOAMAOB | |
| SCHEMBL17517557 | 0.93 | MCL1 (0.50) | MCL1MAOAMAOB | |
| SCHEMBL28805496 | 0.90 | MCL1 (0.47) | MCL1CCNA2CDK2CCNA1MAOA | |
| SCHEMBL27899824 | 0.88 | MCL1 (0.67) | MCL1CCNA2CDK2CCNA1CYP1A2 | |
| SCHEMBL17122538 | 0.84 | ALKBH5 (0.44) | MCL1DPP4 | |
| SCHEMBL20340618 | 0.84 | MCL1 (0.42) | MCL1DPP4 | |
| SCHEMBL27917605 | 0.84 | MCL1 (0.70) | MCL1CCNA2CDK2CCNA1CYP1A2 | |
| SCHEMBL20340628 | 0.77 | MCL1 (0.50) | MCL1CYP1A2CYP2C19CXCR4MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | XINJIANG HUASHIDAN PHARMACEUTICAL RESEARCH CO., LTD (CN) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011614-B2 | Bis-β-carboline compound and preparation method, pharmaceutical composition and use thereof | BRCA1, CA7, DCK | MCL1 209/4885DPP4 747/4885CCNA2 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.